Boston Scientific fills cardiovascular stent gap with Medinol's NIR technology.
This article was originally published in The Gray Sheet
Executive Summary
BOSTON SCIENTIFIC FINDS CARDIOVASCULAR STENT NIRVANA WITH MEDINOL PACT announced Nov. 13. The company gets exclusive rights to Medinol's NIR stent technology under the deal, giving it the missing piece needed to build a stent/angioplasty catheter combination.
You may also be interested in...
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.